CollPlant Biotechnologies Ltd (OPHI)
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Medical - Specialties
CollPlant Biotechnologies Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 3.55 | 3.81 | 3.46 | 3.60 | 26,539 |
| Nov 16, 2026 | 3.60 | 3.84 | 3.09 | 3.28 | 61,945 |
| Nov 13, 2026 | 4.10 | 4.28 | 3.60 | 3.65 | 387,749 |
| Nov 12, 2026 | 4.05 | 4.64 | 4.05 | 4.64 | 439,303 |
| Nov 11, 2026 | 4.03 | 4.20 | 3.86 | 3.96 | 25,053 |
| Nov 10, 2026 | 4.15 | 4.15 | 3.86 | 3.90 | 22,145 |
| Nov 9, 2026 | 4.00 | 4.29 | 3.76 | 4.29 | 23,991 |
| Nov 6, 2026 | 4.18 | 4.19 | 3.85 | 3.97 | 29,217 |
| Nov 5, 2026 | 4.13 | 4.25 | 3.94 | 3.94 | 100,469 |
| Nov 4, 2026 | 4.19 | 4.50 | 4.08 | 4.23 | 36,177 |
| Nov 3, 2026 | 4.01 | 4.44 | 3.99 | 4.11 | 22,970 |
| Nov 2, 2026 | 4.15 | 4.20 | 3.95 | 4.08 | 40,495 |
| Oct 30, 2026 | 4.20 | 4.60 | 4.10 | 4.13 | 44,248 |
| Oct 29, 2026 | 4.10 | 4.70 | 3.87 | 4.40 | 167,097 |
| Oct 28, 2026 | 3.87 | 4.00 | 3.75 | 3.95 | 9,250 |
| Oct 27, 2026 | 3.78 | 3.96 | 3.63 | 3.90 | 38,041 |
| Oct 26, 2026 | 3.67 | 3.91 | 3.65 | 3.75 | 33,811 |
| Oct 23, 2026 | 3.60 | 3.72 | 3.52 | 3.67 | 12,096 |
| Oct 22, 2026 | 3.71 | 3.74 | 3.41 | 3.62 | 10,600 |
| Oct 21, 2026 | 3.80 | 3.81 | 3.55 | 3.75 | 9,684 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Deputy CEO and CFO | Grant/Award | 510.4K | -- | Sep 3, 2026 | |
| VP Legal | Grant/Award | 201.1K | -- | Sep 3, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Rotem Eran Deputy CEO and CFO | 516.4K | -- | FORM 4 |
The Loewenbaum 1992 Trust · joint filing· may incl. warrants· filed Sep 2026 | 359.7K | 17.5% | 13D |
Abelis Bar Berta VP Legal | 206.4K | -- | FORM 4 |
Ami Sagy · may incl. warrants· filed Oct 2026 | 163.7K | 5.7% | 13G |
VILLERE ST DENIS J & CO LLC | 78.1K | -- | 13F |
PINNACLE ASSOCIATES LTD | 71.0K | -- | 13F |
Shlomi Ruty Ben Director | 66.5K | -- | FORM 4 |
Roumell Asset Management, LLC ("RAM") 52-2145132 · may incl. warrants· stale · filed Feb 2024 | 43.3K | 3.8% | 13G |
Evans Hugh M Director | 31.6K | -- | FORM 4 |
JANE STREET GROUP, LLC | 23.1K | -- | 13F |
Insiders
- Rotem EranDeputy CEO and CFO
- Abelis Bar BertaVP Legal
- Shlomi Ruty BenDirector
- Evans Hugh MDirector
- Tal YehielChief Executive Officer, Director
- Seror JasmineVP Product Development
- Bensimon PhilippeVP Regulations and QA
- Fahimipoor OrenVP Operations
- Bagley BowmanVP Commercial North America
- Havron AvrahamDirector
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe.
The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen.
Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores.
The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
based on 3.08M shares outstanding
30d Avg
74.34K
60d Avg
65.04K
90d Avg
396.15K
Signal8's dilution snapshot of OPHI as of Dec 31, 2025 records an effective F-3 shelf registration (effective Jul 16, 2026), 12 outstanding warrant series and a PIPE closed Oct 14, 2026, from SEC filings. CollPlant Biotechnologies Ltd (NASDAQ: OPHI) traded at $4.64 on Nov 12, 2026, up 17.17% from the previous close of $3.96. 52-week range: $2.64 to $22.50. The company is in the Healthcare sector (Biotechnology).